JP2014110810A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014110810A5 JP2014110810A5 JP2014049395A JP2014049395A JP2014110810A5 JP 2014110810 A5 JP2014110810 A5 JP 2014110810A5 JP 2014049395 A JP2014049395 A JP 2014049395A JP 2014049395 A JP2014049395 A JP 2014049395A JP 2014110810 A5 JP2014110810 A5 JP 2014110810A5
- Authority
- JP
- Japan
- Prior art keywords
- factor
- antibody
- binding fragment
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 33
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 150000001413 amino acids Chemical class 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 208000028867 ischemia Diseases 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 230000024203 complement activation Effects 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 208000030533 eye disease Diseases 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010002199 Anaphylactic shock Diseases 0.000 claims 2
- 206010002329 Aneurysm Diseases 0.000 claims 2
- 208000028185 Angioedema Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010013700 Drug hypersensitivity Diseases 0.000 claims 2
- 208000037487 Endotoxemia Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010021137 Hypovolaemia Diseases 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 208000034486 Multi-organ failure Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 2
- 206010061372 Streptococcal infection Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 206010000891 acute myocardial infarction Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000002612 cardiopulmonary effect Effects 0.000 claims 2
- 239000002872 contrast media Substances 0.000 claims 2
- 201000005311 drug allergy Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 238000001631 haemodialysis Methods 0.000 claims 2
- 230000000322 hemodialysis Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000010410 reperfusion Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 102000003706 Complement factor D Human genes 0.000 claims 1
- 108090000059 Complement factor D Proteins 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85650506P | 2006-11-02 | 2006-11-02 | |
| US60/856,505 | 2006-11-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012235325A Division JP2013027404A (ja) | 2006-11-02 | 2012-10-25 | ヒト化抗ｄ因子抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015171685A Division JP2015214591A (ja) | 2006-11-02 | 2015-09-01 | ヒト化抗ｄ因子抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014110810A JP2014110810A (ja) | 2014-06-19 |
| JP2014110810A5 true JP2014110810A5 (enExample) | 2014-07-31 |
| JP5918794B2 JP5918794B2 (ja) | 2016-05-18 |
Family
ID=39345075
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535444A Withdrawn JP2010508819A (ja) | 2006-11-02 | 2007-10-31 | ヒト化抗ｄ因子抗体 |
| JP2012235324A Expired - Fee Related JP5474158B2 (ja) | 2006-11-02 | 2012-10-25 | ヒト化抗ｄ因子抗体 |
| JP2012235325A Pending JP2013027404A (ja) | 2006-11-02 | 2012-10-25 | ヒト化抗ｄ因子抗体 |
| JP2014049395A Active JP5918794B2 (ja) | 2006-11-02 | 2014-03-12 | ヒト化抗ｄ因子抗体 |
| JP2015171685A Withdrawn JP2015214591A (ja) | 2006-11-02 | 2015-09-01 | ヒト化抗ｄ因子抗体 |
| JP2017157499A Pending JP2017200492A (ja) | 2006-11-02 | 2017-08-17 | ヒト化抗ｄ因子抗体 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535444A Withdrawn JP2010508819A (ja) | 2006-11-02 | 2007-10-31 | ヒト化抗ｄ因子抗体 |
| JP2012235324A Expired - Fee Related JP5474158B2 (ja) | 2006-11-02 | 2012-10-25 | ヒト化抗ｄ因子抗体 |
| JP2012235325A Pending JP2013027404A (ja) | 2006-11-02 | 2012-10-25 | ヒト化抗ｄ因子抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015171685A Withdrawn JP2015214591A (ja) | 2006-11-02 | 2015-09-01 | ヒト化抗ｄ因子抗体 |
| JP2017157499A Pending JP2017200492A (ja) | 2006-11-02 | 2017-08-17 | ヒト化抗ｄ因子抗体 |
Country Status (35)
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2026073B1 (en) * | 2000-04-29 | 2016-03-30 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| ES2551202T5 (es) | 2005-11-04 | 2018-11-30 | Genentech, Inc. | Uso de inhibidores de la vía del complemento para tratar enfermedades oculares |
| AU2007261315B2 (en) | 2006-06-21 | 2012-10-25 | Musc Foundation For Research Development | Targeting complement factor H for treatment of diseases |
| CN106084054A (zh) | 2006-11-02 | 2016-11-09 | 健泰科生物技术公司 | 人源化的抗‑d因子抗体 |
| AR066660A1 (es) * | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
| CR20170001A (es) * | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| CN102076355B (zh) * | 2008-04-29 | 2014-05-07 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| SG191639A1 (en) * | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| AU2009256246B2 (en) * | 2008-06-03 | 2013-07-18 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| AU2009268585C1 (en) * | 2008-07-08 | 2014-10-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| WO2010028028A1 (en) | 2008-09-08 | 2010-03-11 | Virginia Tech Intellectual Properties | Systems, devices, and methods for managing energy usage |
| PE20120586A1 (es) | 2009-01-29 | 2012-06-17 | Abbott Lab | Proteinas de union a il-1 |
| AU2010266127B2 (en) | 2009-07-02 | 2015-11-05 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| KR20110020642A (ko) | 2009-08-24 | 2011-03-03 | 삼성전자주식회사 | 사용자 접근을 인식하여 반응하는 ｇｕｉ제공 장치 및 방법 |
| TW201119673A (en) * | 2009-09-01 | 2011-06-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| TW201124427A (en) * | 2009-10-15 | 2011-07-16 | Abbott Lab | IL-1 binding proteins |
| UY32948A (es) * | 2009-10-15 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| US20110165648A1 (en) | 2009-11-04 | 2011-07-07 | Menno Van Lookeren Campagne | Co-crystal structure of factor D and anti-factor D antibody |
| EA201290286A1 (ru) | 2009-11-05 | 2013-01-30 | Алексион Кембридж Корпорейшн | Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза |
| SG185483A1 (en) | 2010-05-14 | 2012-12-28 | Univ Colorado Regents | Improved complement receptor 2 (cr2) targeting groups |
| EP2585110A4 (en) | 2010-06-22 | 2014-01-22 | Univ Colorado Regents | ANTIBODIES AGAINST THE C3D FRAGMENT OF THE COMPLEMENT COMPONENT 3 |
| TW201206473A (en) | 2010-08-03 | 2012-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| CN103260639A (zh) | 2010-08-26 | 2013-08-21 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| MY163368A (en) | 2010-12-21 | 2017-09-15 | Abbvie Inc | Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use |
| WO2012093101A1 (en) | 2011-01-04 | 2012-07-12 | Novartis Ag | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd) |
| WO2013102042A2 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual specific binding proteins directed against il-13 and/or il-17 |
| WO2014002052A1 (en) | 2012-06-28 | 2014-01-03 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
| JP6273274B2 (ja) | 2012-06-28 | 2018-01-31 | ノバルティス アーゲー | 補体経路モジュレーターおよびその使用 |
| ES2712190T3 (es) | 2012-06-28 | 2019-05-09 | Novartis Ag | Moduladores de la vía del complemento y sus usos |
| JP6155332B2 (ja) | 2012-06-28 | 2017-06-28 | ノバルティス アーゲー | ピロリジン誘導体、および補体経路調節因子としてのその使用 |
| JP6209605B2 (ja) | 2012-06-28 | 2017-10-04 | ノバルティス アーゲー | ピロリジン誘導体、および補体経路調節因子としてのその使用 |
| EA201590200A1 (ru) | 2012-07-12 | 2015-08-31 | Новартис Аг | Модуляторы пути активации комплемента и их применение |
| WO2014011955A2 (en) | 2012-07-12 | 2014-01-16 | Abbvie, Inc. | Il-1 binding proteins |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| AU2013302441B2 (en) | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
| WO2014047311A1 (en) | 2012-09-19 | 2014-03-27 | Genentech, Inc. | Methods and compositions for preventing norleucine misincorporation into proteins |
| HK1212359A1 (en) | 2012-11-01 | 2016-06-10 | Abbvie Inc. | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
| JP2016522793A (ja) | 2013-03-15 | 2016-08-04 | アッヴィ・インコーポレイテッド | ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質 |
| AU2014306002B2 (en) | 2013-08-07 | 2017-05-25 | Alexion Pharmaceuticals, Inc. | Atypical hemolytic uremic syndrome (aHUS) biomarker proteins |
| CR20160132A (es) * | 2013-08-12 | 2016-08-25 | Genentech Inc | Composiciones y método para tratar condiciones asociadas con el complemento |
| SG11201608868PA (en) | 2014-05-01 | 2016-11-29 | Genentech Inc | Anti-factor d antibody variants and uses thereof |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| EP3368074A2 (en) | 2015-10-30 | 2018-09-05 | Hoffmann-La Roche AG | Anti-factor d antibodies and conjugates |
| HK1257426A1 (zh) * | 2015-10-30 | 2019-10-18 | 豪夫迈‧罗氏有限公司 | 抗-因子d抗体制剂 |
| EP3368090A1 (en) | 2015-10-30 | 2018-09-05 | H. Hoffnabb-La Roche Ag | Anti-factor d antibody variant conjugates and uses thereof |
| EP3368682B1 (en) | 2015-10-30 | 2019-12-11 | H. Hoffnabb-La Roche Ag | Methods of measuring factor d activity and potency of factor d inhibitors |
| SI3368578T1 (sl) | 2015-10-30 | 2021-08-31 | F. Hoffmann-La Roche Ag | Protitelesa proti HtrA1 in postopki uporabe |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| CN108934169A (zh) | 2016-01-20 | 2018-12-04 | 维特里萨医疗公司 | 用于抑制因子d的组合物和方法 |
| EP3445783A2 (en) | 2016-04-18 | 2019-02-27 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human cd40 and uses thereof |
| HUE058657T2 (hu) | 2016-06-23 | 2022-09-28 | Jiangsu Hengrui Medicine Co | Lag-3 antitest, antigénkötõ fragmentuma és gyógyszerészeti alkalmazása |
| US11007254B2 (en) | 2016-10-17 | 2021-05-18 | Musc Foundation For Research Development | Compositions and methods for treating central nervous system injury |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| CA3053155A1 (en) | 2017-02-10 | 2018-08-16 | The Trustees Of The University Of Pennsylvania | Anti-factor d antibodies and uses thereof |
| CN106905431B (zh) * | 2017-04-10 | 2020-01-17 | 旭华（上海）生物研发中心有限公司 | 抗人补体d因子的单克隆抗体及其用途 |
| AU2018250695A1 (en) | 2017-04-14 | 2019-11-07 | Kodiak Sciences Inc. | Complement factor D antagonist antibodies and conjugates thereof |
| FR3071483B1 (fr) * | 2017-09-27 | 2020-11-27 | Airbus Operations Sas | Systeme de surveillance de braquage d'une roulette de train d'atterrissage d'un aeronef |
| WO2019109238A1 (en) * | 2017-12-05 | 2019-06-13 | Lyvgen Biopharma Co., Ltd. | Anti-cd137 antibodies and uses thereof |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| US11166910B2 (en) | 2019-01-25 | 2021-11-09 | Nordiccan A/S | Cannabinoid chewing gum with sugar alcohols |
| CN110240652B (zh) * | 2019-06-05 | 2022-09-06 | 百奥泰生物制药股份有限公司 | 抗补体d因子抗体及其应用 |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN117425673A (zh) * | 2021-04-09 | 2024-01-19 | 武田药品工业株式会社 | 靶向补体因子d的抗体和其用途 |
| CN119176879B (zh) * | 2024-09-05 | 2025-08-05 | 西安市中心血站（陕西省血液中心） | 一种中和抗d抗体的抗独特型抗体及其应用 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5256642A (en) * | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| IL94611A (en) | 1989-06-05 | 1994-12-29 | Organogenesis Inc | Medium for cell cultures containing insulin or growth factor similar to insulin, transferrin or iron ion, triiodothyronine or thyroxine and method of use |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5456909A (en) * | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
| EP0656789B1 (en) | 1992-08-21 | 1997-12-17 | Genentech, Inc. | Method for treating a lfa-1-mediated disorder |
| US5861156A (en) * | 1993-01-08 | 1999-01-19 | Creative Biomolecules | Methods of delivering agents to target cells |
| US5856300A (en) * | 1994-05-12 | 1999-01-05 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
| US5679546A (en) * | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
| US5627264A (en) * | 1994-03-03 | 1997-05-06 | Alexion Pharmaceuticals, Inc. | Chimeric complement inhibitor proteins |
| DE69533921T2 (de) * | 1994-03-23 | 2005-12-01 | Alexion Pharmaceuticals, Inc., New Haven | Verfahren zur reduktion von fehlfunktionen des immunsystems und der hämostase während des extrakorporalen kreislaufs |
| US5534615A (en) * | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5897475A (en) * | 1994-10-05 | 1999-04-27 | Antex Biologics, Inc. | Vaccines comprising enhanced antigenic helicobacter spp. |
| WO2002000690A2 (en) | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| WO2002008284A2 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| US20050197285A1 (en) * | 1997-03-07 | 2005-09-08 | Rosen Craig A. | Human secreted proteins |
| WO1999040100A1 (en) * | 1998-02-09 | 1999-08-12 | Human Genome Sciences, Inc. | 45 human secreted proteins |
| US6472520B2 (en) * | 1997-03-21 | 2002-10-29 | The Trustees Of Columbia University In The City Of New York | Rat PEG-3 promoter |
| US6333034B1 (en) * | 1997-08-26 | 2001-12-25 | Gliatech, Inc. | Process for inhibiting complement activation via the alternative pathway |
| US6410708B1 (en) * | 1997-11-21 | 2002-06-25 | Genentech, Inc. | Nucleic acids encoding A-33 related antigen polypeptides |
| US8007798B2 (en) * | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
| US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
| ES2305608T3 (es) | 1997-11-21 | 2008-11-01 | Genentech, Inc. | Antigenos tipo a-33 y sus utilizaciones farmacologicas. |
| US7419663B2 (en) * | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
| US7192589B2 (en) * | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
| US7282565B2 (en) * | 1998-03-20 | 2007-10-16 | Genentech, Inc. | PRO362 polypeptides |
| US7112327B2 (en) | 1998-02-20 | 2006-09-26 | Tanox, Inc. | Inhibition of complement activation |
| US6956107B2 (en) | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
| DE69939813D1 (de) * | 1998-02-20 | 2008-12-11 | Tanox Inc | Inhibitoren der komplement-aktivierung |
| DK1490386T3 (da) | 1998-03-10 | 2008-12-15 | Genentech Inc | Nyt polypeptid og nukleinsyrer kodende for dette |
| CA2340794A1 (en) | 1998-08-27 | 2000-03-09 | Incyte Pharmaceuticals, Inc. | Protein transport-associated molecules |
| CA2348757A1 (en) | 1998-12-16 | 2000-06-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| JP3993746B2 (ja) | 1998-12-22 | 2007-10-17 | ジェネンテック・インコーポレーテッド | 腫瘍性細胞成長阻害のための組成物及び方法 |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| KR20010103046A (ko) | 1999-03-08 | 2001-11-17 | 제넨테크, 인크. | 면역 관련 질환 치료용 조성물 및 치료 방법 |
| CN1637019A (zh) | 1999-03-11 | 2005-07-13 | Rmf迪克塔吉恩有限公司 | 血管粘着分子及其功能的调节 |
| US6642353B1 (en) * | 1999-03-17 | 2003-11-04 | Chugai Seiyaku Kabushiki Kaisha | Peptide ligands for the erythropoietin receptor |
| AU2883900A (en) | 1999-07-07 | 2001-01-30 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| AU1604401A (en) | 1999-11-19 | 2001-05-30 | Human Genome Sciences, Inc. | 18 human secreted proteins |
| EP1686134A3 (en) | 1999-12-01 | 2006-08-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| ATE435873T1 (de) * | 2000-03-23 | 2009-07-15 | Genentech Inc | Anti-c2/c2a inhibitoren zur komplement aktivierung |
| EP2026073B1 (en) * | 2000-04-29 | 2016-03-30 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| AU2001296594A1 (en) | 2000-10-10 | 2002-04-22 | Tanox, Inc. | Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
| AR035352A1 (es) | 2000-10-13 | 2004-05-12 | Biogen Inc | Anticuerpos anti-lt-beta-r humanizados |
| US7432356B2 (en) * | 2001-08-17 | 2008-10-07 | Genentech, Inc. | Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b |
| AR040778A1 (es) | 2002-08-06 | 2005-04-20 | Glaxo Group Ltd | Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina). |
| US20040152105A1 (en) * | 2002-09-06 | 2004-08-05 | Cytos Biotechnology Ag. | Immune modulatory compounds and methods |
| US7816497B2 (en) * | 2002-10-30 | 2010-10-19 | University Of Kentucky | Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration |
| RU2232991C1 (ru) * | 2003-04-09 | 2004-07-20 | Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" | Способ определения функциональной активности фактора d комплемента человека |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| WO2005014849A2 (en) * | 2003-07-03 | 2005-02-17 | Euro-Celtique, S.A. | Genes associated with responses to neuropathic pain |
| US7923010B2 (en) | 2003-09-11 | 2011-04-12 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune diseases and conditions |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| WO2006062716A2 (en) | 2004-11-18 | 2006-06-15 | Yale University | Methods and compositions for treating ocular disorders |
| WO2006071856A2 (en) | 2004-12-23 | 2006-07-06 | Glycofi, Inc. | Immunoglobulins comprising predominantly a man5glcnac2 glycoform |
| EP2357257B1 (en) | 2005-02-14 | 2019-07-31 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
| FI118793B (fi) * | 2005-07-11 | 2008-03-31 | Olli Friman | Rullaluistimen pyörän vierintälaakerin suojalevy |
| JP5345849B2 (ja) | 2005-10-08 | 2013-11-20 | ポテンシア ファーマシューティカルズ， インコーポレイテッド | 眼の障害のためのコンプスタチンおよびそのアナログ |
| ES2551202T5 (es) * | 2005-11-04 | 2018-11-30 | Genentech, Inc. | Uso de inhibidores de la vía del complemento para tratar enfermedades oculares |
| US20070190057A1 (en) | 2006-01-23 | 2007-08-16 | Jian Wu | Methods for modulating mannose content of recombinant proteins |
| US7941135B2 (en) | 2006-03-22 | 2011-05-10 | Alcatel-Lucent Usa Inc. | Methods of performing live monitoring of a wireless communication network |
| CN106084054A (zh) * | 2006-11-02 | 2016-11-09 | 健泰科生物技术公司 | 人源化的抗‑d因子抗体 |
| AR066660A1 (es) | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
| CR20170001A (es) * | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
-
2007
- 2007-10-31 CN CN201610570102.6A patent/CN106084054A/zh active Pending
- 2007-10-31 WO PCT/US2007/083172 patent/WO2008055206A2/en not_active Ceased
- 2007-10-31 CA CA2939806A patent/CA2939806A1/en not_active Abandoned
- 2007-10-31 EP EP18190268.5A patent/EP3466971A1/en not_active Withdrawn
- 2007-10-31 CN CN200780048936.XA patent/CN101589063B/zh not_active Expired - Fee Related
- 2007-10-31 CA CA2667997A patent/CA2667997C/en not_active Expired - Fee Related
- 2007-10-31 PL PL07868632T patent/PL2097455T3/pl unknown
- 2007-10-31 SI SI200731587T patent/SI2097455T1/sl unknown
- 2007-10-31 DK DK15151317.3T patent/DK2907827T3/da active
- 2007-10-31 PL PL15151317T patent/PL2907827T3/pl unknown
- 2007-10-31 PT PT78686326T patent/PT2097455E/pt unknown
- 2007-10-31 UA UAA200905597A patent/UA101603C2/ru unknown
- 2007-10-31 SI SI200732083T patent/SI2907827T1/sl unknown
- 2007-10-31 KR KR1020197000043A patent/KR20190003860A/ko not_active Ceased
- 2007-10-31 KR KR1020097011297A patent/KR20090078364A/ko not_active Withdrawn
- 2007-10-31 ES ES15151317T patent/ES2700609T3/es active Active
- 2007-10-31 PT PT15151317T patent/PT2907827T/pt unknown
- 2007-10-31 TW TW107108695A patent/TW201843170A/zh unknown
- 2007-10-31 UA UAA201214158A patent/UA116614C2/uk unknown
- 2007-10-31 RU RU2009120699A patent/RU2474589C9/ru not_active IP Right Cessation
- 2007-10-31 EP EP15151317.3A patent/EP2907827B1/en active Active
- 2007-10-31 EP EP12152860A patent/EP2471818A1/en not_active Ceased
- 2007-10-31 KR KR1020177026557A patent/KR20170110727A/ko not_active Ceased
- 2007-10-31 KR KR1020147019915A patent/KR20140101873A/ko not_active Withdrawn
- 2007-10-31 AR ARP070104846A patent/AR063760A1/es not_active Application Discontinuation
- 2007-10-31 MX MX2009004665A patent/MX2009004665A/es active IP Right Grant
- 2007-10-31 EP EP07868632.6A patent/EP2097455B1/en active Active
- 2007-10-31 PE PE2007001490A patent/PE20081259A1/es active IP Right Grant
- 2007-10-31 LT LTEP15151317.3T patent/LT2907827T/lt unknown
- 2007-10-31 MY MYPI20091788A patent/MY157948A/en unknown
- 2007-10-31 AU AU2007313685A patent/AU2007313685C1/en not_active Ceased
- 2007-10-31 KR KR1020167020466A patent/KR20160092061A/ko not_active Ceased
- 2007-10-31 JP JP2009535444A patent/JP2010508819A/ja not_active Withdrawn
- 2007-10-31 PE PE2012000037A patent/PE20121034A1/es active IP Right Grant
- 2007-10-31 KR KR1020157009721A patent/KR101645144B1/ko not_active Expired - Fee Related
- 2007-10-31 CN CN201610570481.9A patent/CN106188304A/zh active Pending
- 2007-10-31 CN CN201610570104.5A patent/CN106084055A/zh active Pending
- 2007-10-31 TW TW105127533A patent/TW201716437A/zh unknown
- 2007-10-31 NZ NZ576812A patent/NZ576812A/en not_active IP Right Cessation
- 2007-10-31 TW TW103141058A patent/TW201534620A/zh unknown
- 2007-10-31 CN CN201610570520.5A patent/CN106188299A/zh active Pending
- 2007-10-31 US US11/931,060 patent/US8067002B2/en not_active Expired - Fee Related
- 2007-10-31 TW TW100142121A patent/TWI472535B/zh not_active IP Right Cessation
- 2007-10-31 NZ NZ609813A patent/NZ609813A/en not_active IP Right Cessation
- 2007-10-31 CN CN201610569910.0A patent/CN106188303A/zh active Pending
- 2007-10-31 DK DK07868632.6T patent/DK2097455T3/en active
- 2007-10-31 CL CL200703161A patent/CL2007003161A1/es unknown
- 2007-10-31 BR BRPI0716299-5A2A patent/BRPI0716299A2/pt active Search and Examination
- 2007-10-31 TW TW096141085A patent/TWI391401B/zh not_active IP Right Cessation
- 2007-10-31 ES ES07868632.6T patent/ES2525477T3/es active Active
- 2007-10-31 NZ NZ596042A patent/NZ596042A/xx not_active IP Right Cessation
- 2007-10-31 RS RS20181476A patent/RS58233B1/sr unknown
- 2007-10-31 MY MYPI2013002530A patent/MY183804A/en unknown
- 2007-10-31 CN CN201510511513.3A patent/CN105085682A/zh active Pending
-
2009
- 2009-05-03 IL IL198512A patent/IL198512A/en active IP Right Review Request
- 2009-05-05 ZA ZA2009/03088A patent/ZA200903088B/en unknown
- 2009-05-26 CR CR10827A patent/CR10827A/es unknown
- 2009-05-29 CO CO09055632A patent/CO6190543A2/es active IP Right Grant
- 2009-05-29 NO NO20092121A patent/NO20092121L/no not_active Application Discontinuation
- 2009-06-01 MA MA31941A patent/MA30962B1/fr unknown
- 2009-06-02 EC EC2009009379A patent/ECSP099379A/es unknown
-
2011
- 2011-01-14 US US13/007,142 patent/US8187604B2/en not_active Expired - Fee Related
- 2011-01-14 US US13/007,061 patent/US8193329B2/en not_active Expired - Fee Related
-
2012
- 2012-05-01 US US13/461,253 patent/US8372403B2/en not_active Expired - Fee Related
- 2012-10-25 JP JP2012235324A patent/JP5474158B2/ja not_active Expired - Fee Related
- 2012-10-25 JP JP2012235325A patent/JP2013027404A/ja active Pending
- 2012-11-06 RU RU2012147286A patent/RU2678802C2/ru not_active IP Right Cessation
-
2013
- 2013-02-05 US US13/759,613 patent/US8753826B2/en not_active Expired - Fee Related
- 2013-02-05 ZA ZA2013/00949A patent/ZA201300949B/en unknown
-
2014
- 2014-03-12 JP JP2014049395A patent/JP5918794B2/ja active Active
- 2014-05-20 US US14/282,063 patent/US20140303355A1/en not_active Abandoned
-
2015
- 2015-04-29 AR ARP150101290A patent/AR100225A2/es unknown
- 2015-04-29 IL IL238517A patent/IL238517B/en active IP Right Grant
- 2015-07-06 US US14/792,197 patent/US20150376295A1/en not_active Abandoned
- 2015-07-06 US US14/792,213 patent/US20160002352A1/en not_active Abandoned
- 2015-07-06 US US14/792,236 patent/US20160002353A1/en not_active Abandoned
- 2015-08-12 PH PH12015501763A patent/PH12015501763A1/en unknown
- 2015-09-01 JP JP2015171685A patent/JP2015214591A/ja not_active Withdrawn
-
2016
- 2016-03-29 HK HK16103589.3A patent/HK1215712A1/zh unknown
- 2016-07-29 US US15/224,366 patent/US20170166630A1/en not_active Abandoned
- 2016-12-23 HK HK16114632.7A patent/HK1226417A1/zh unknown
-
2017
- 2017-08-17 JP JP2017157499A patent/JP2017200492A/ja active Pending
- 2017-08-24 IL IL254137A patent/IL254137A0/en unknown
-
2018
- 2018-11-23 HR HRP20181969TT patent/HRP20181969T1/hr unknown
-
2019
- 2019-01-29 RU RU2019102393A patent/RU2019102393A/ru not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014110810A5 (enExample) | ||
| JP2013027404A5 (enExample) | ||
| RU2019102393A (ru) | Гуманизированные антитела к фактору d и их применения | |
| JP7357038B2 (ja) | 改善されたｔｎｆ結合因子 | |
| AU2015279128B2 (en) | Multispecific antibody constructs | |
| JP2018502060A5 (enExample) | ||
| CA3080860A1 (en) | Cd47 antigen-binding molecules | |
| JP2016524592A5 (enExample) | ||
| JP2017529097A5 (enExample) | ||
| JP2014518883A5 (enExample) | ||
| JP2011514150A5 (enExample) | ||
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| JP2014526898A5 (enExample) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| RU2015143886A (ru) | Антитела к тау и способы применения | |
| JP2016525502A5 (enExample) | ||
| RU2018102798A (ru) | Антитела к фактору xi и способы их применения | |
| CN104507964A (zh) | P2x7受体拮抗剂和激动剂 | |
| JP2019504822A5 (enExample) | ||
| JP2016530223A5 (enExample) | ||
| JP2014506259A5 (enExample) | ||
| JP2015536951A5 (enExample) | ||
| JP2017511140A5 (enExample) | ||
| JP2016006052A5 (enExample) | ||
| JPWO2020059847A5 (enExample) |